Weekly Research Analysts’ Ratings Changes for Alkermes (ALKS)

Alkermes (NASDAQ: ALKS) recently received a number of ratings updates from brokerages and research firms:

• 7/13/2026 – Alkermes had its price target raised by Needham & Company LLC from $61.00 to $62.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Alkermes is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $60.00 price target on the stock.
• 7/2/2026 – Alkermes had its price target raised by Mizuho from $53.00 to $65.00. They now have an “outperform” rating on the stock.
• 6/29/2026 – Alkermes had its price target raised by Wells Fargo & Company from $44.00 to $65.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Alkermes had its “underperform” rating reaffirmed by Bank of America Corporation.
• 6/24/2026 – Alkermes had its price target raised by Needham & Company LLC from $54.00 to $61.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Alkermes had its price target raised by TD Cowen from $42.00 to $50.00. They now have a “buy” rating on the stock.
• 6/18/2026 – Alkermes had its “neutral” rating reaffirmed by HC Wainwright.
• 6/18/2026 – Alkermes had its price target raised by Needham & Company LLC from $50.00 to $54.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Alkermes had its price target raised by Royal Bank Of Canada from $45.00 to $56.00. They now have an “outperform” rating on the stock.

Insider Transactions at Alkermes

In related news, EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $54.03, for a total value of $109,897.02. Following the completion of the transaction, the executive vice president directly owned 227,490 shares in the company, valued at approximately $12,291,284.70. This represents a 0.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher I. Wright sold 2,000 shares of the stock in a transaction on Friday, June 12th. The shares were sold at an average price of $45.10, for a total transaction of $90,200.00. Following the completion of the transaction, the director owned 25,680 shares of the company’s stock, valued at approximately $1,158,168. This represents a 7.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 35,102 shares of company stock valued at $1,494,410. 4.59% of the stock is owned by corporate insiders.

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.